Stocks | | | The hotel industry may not be as flashy as some other areas for investors. Hotels are rarely the biggest stock gainers, best growth stocks, or the most active stocks on Wall Street, but that doesn’t mean that it’s not worth investing in them. There’s a lot of momentum in the hotel industry—and that means there is potential for stock returns. When investing in the hotel industry, be aware that the hotel industry is cyclical, since its growth has a high correlation with that of the overall stock market. This means that market volatility caused by analyst reports and the latest news is likely to cause volatility in the hotel industry as well. For example, during the financial crisis of 2008, the hotel industry took a major hit. But as part of a diversified portfolio, hotel stocks can be a great investment. Read the Full Story |
|
From Our PartnersHackers and cyberterrorists are attacking America. They broke into computers at Lockheed Martin and Boeing to steal blueprints for military aircraft. Another "Cyber 9/11" is imminent. And the Trump administration is pouring $80 billion into cyberdefense. I've pinpointed the #1 cyberdefense contractor to receive that windfall spending -- and deliver investors up to 700% profits. | | Details here. |
|
Stocks | | |
One of the most interesting components of trading is that each and every day there are new factors that directly influence the prices of securities in the market. That means that every morning at the opening bell, there are plenty of new opportunities that traders can take advantage of. Part of be... Read the Full Story |
|
Markets | | |
As a trader, it can be tough to find opportunities in the market if there isn’t a lot of trading volume that day. Even if you think you found a trading setup with a lot of potential, it won’t go anywhere without trading volume. A stock without volume is akin to a car without gasoline. ... Read the Full Story |
|
From Our PartnersIf you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks. | | Then go here ASAP. |
|
Markets | | | Shares of DocuSign (NASDAQ: DOCU) finished last week at all-time highs after smashing analyst estimates for their earnings and revenue in their Q3 report which was released after Thursday’s session. This comes after upward guidance from management at their last quarterly release in September a... Read the Full Story |
|
Markets | | |
If someone were to say that we live in a “post-unicorn era,” they probably wouldn't be too far off. Some have been projecting such an era as far back as 2016, and with the recent issues surrounding WeWork, it's easy to see that if the unicorn era weren't dead before, it probably is now... Read the Full Story |
|
From Our PartnersHundreds of thousands of Americans have been hit by a wave of wealth. Over the past year, the U.S. has minted an average of 1,800 new millionaires a day. How did they do it? For the first time in history, two of these millionaire investors have joined forces to help you learn the secret moneymaking strategy of the wealthy and connected. | | Click here to watch their presentation. |
|
The Early Bird Stock Of The Day Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. | | View Today's Stock Pick |
|
